Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (481-490 of 535) with videos related to

Pageof 54
Sort By:
Lancet (London, England)|May 10, 2016
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trialDinesh Khanna, Christopher P Denton, Angelika Jahreis, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Annals of the Rheumatic Diseases|January 28, 2025
EULAR recommendations for the treatment of systemic sclerosis: 2023 updateFrancesco Del Galdo, Alain Lescoat, Philip G Conaghan, et al.
Clinical Rheumatology|May 22, 2019
Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher studyJelena Blagojevic, G Abignano, J Avouac, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
RMD Open|August 13, 2025
Assessing the <i>MUC5B</i> promoter variant in a large cohort of systemic sclerosis-associated interstitial lung diseaseCarlos Rosa-Baez, Carlos Rangel-Pelaez, Inmaculada Rodriguez-Martin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2024
Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromesR Knobler, M Geroldinger-Simić, A Kreuter, et al.
NPJ Genomic Medicine|October 5, 2022
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosisMartin Kerick, Marialbert Acosta-Herrera, Carmen Pilar Simeón-Aznar, et al.
Rheumatology (Oxford, England)|November 5, 2019
Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group studyVeronika K Jaeger, Mohammed Tikly, Dong Xu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 14, 2025
Distinct effects of complement C4A and C4B copy number in Systemic Sclerosis serological and clinical subtypesJavier Martínez-López, Carlos Rangel-Peláez, Inmaculada Rodriguez-Martin, et al.
Pageof 54

Showing results (481-490 of 535) with videos related to

Sort By:
Pageof 54
Lancet (London, England)|May 10, 2016
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trialDinesh Khanna, Christopher P Denton, Angelika Jahreis, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Annals of the Rheumatic Diseases|January 28, 2025
EULAR recommendations for the treatment of systemic sclerosis: 2023 updateFrancesco Del Galdo, Alain Lescoat, Philip G Conaghan, et al.
Clinical Rheumatology|May 22, 2019
Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher studyJelena Blagojevic, G Abignano, J Avouac, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
RMD Open|August 13, 2025
Assessing the <i>MUC5B</i> promoter variant in a large cohort of systemic sclerosis-associated interstitial lung diseaseCarlos Rosa-Baez, Carlos Rangel-Pelaez, Inmaculada Rodriguez-Martin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 8, 2024
Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromesR Knobler, M Geroldinger-Simić, A Kreuter, et al.
NPJ Genomic Medicine|October 5, 2022
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosisMartin Kerick, Marialbert Acosta-Herrera, Carmen Pilar Simeón-Aznar, et al.
Rheumatology (Oxford, England)|November 5, 2019
Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group studyVeronika K Jaeger, Mohammed Tikly, Dong Xu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 14, 2025
Distinct effects of complement C4A and C4B copy number in Systemic Sclerosis serological and clinical subtypesJavier Martínez-López, Carlos Rangel-Peláez, Inmaculada Rodriguez-Martin, et al.
Pageof 54